Clinical Trial Detail

NCT ID NCT02975934
Title A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements Yes
Sponsors Clovis Oncology, Inc
Indications

prostate adenocarcinoma

prostate carcinoma

Therapies

Rucaparib

Docetaxel

Enzalutamide

Abiraterone

Age Groups: senior adult

Additional content available in CKB BOOST